Jason Haas

Director Jason Haas sold 6,461 shares for $1,651,320.20 at LGND; retains 4,981 non-derivative shares plus 13,276 derivative holdings.

Jason Haas sold 6,461 shares across 2 transactions on 2026-06-12 at prices of $255.01 and $256.08, for a combined $1,651,320.20. His non-derivative holdings dropped from 11,442 to 4,981 shares, representing a 56.5% reduction of his non-derivative position. However, the FLAG section clarifies that his overall position remains substantial: he retains 7,138 and 6,138 non-qualified stock options, totaling 13,276 derivative shares. The current stock price of $253.25 is only 2.2% below the 52-week high of $259.03, and the stock has advanced 18.8% over the past 30 days and 20.0% over 90 days. Fundamentals show annual revenue growth of 60.4% but negative net income of $-13,345,000.00 on $51,722,000.00 quarterly revenue, with a P/E of 33.06. This sale represents a scheduled reduction of a specific tranche of shares, not a portfolio exit, given his substantial remaining derivative position.

Odyssey Therapeutics CFO Jason Haas makes 4th open-market purchase in 36 months, adding 1,000 shares for ~$20K in newly listed stock.

Odyssey Therapeutics CFO Jason Haas has now made four open-market purchases over the past three years, establishing a consistent pattern of buying company shares with his own capital. This latest purchase adds modestly to his position in a stock that has only a single day of trading history as a newly listed company, making any price context limited. The stock is currently trading below the price Haas paid for this purchase, though with only one trading day elapsed since the transaction, it is far too early to draw any meaningful conclusions from that price movement. His prior buying history shows a conflicted picture on timing: near-term returns following his past purchases have been notably positive, while longer-horizon returns have been sharply negative — meaning these earlier buys tended to work in the short run but deteriorated over a quarterly timeframe. Investors should weigh this repeat-buyer pattern against that mixed longer-term track record, particularly given how little price history currently exists for this recently listed company.

Syros CFO Haas bought 100,000 shares in 3 transactions totaling $161,239.79 on Sept 10-12.

Jason Haas, Chief Financial Officer of Syros Pharmaceuticals, completed 3 separate purchases totaling 100,000 shares for $161,239.79 between September 10-12, 2024, increasing his holdings from 24,552 shares to 124,552 shares (+407.3%). The blended average purchase price was $1.61, while the stock now trades at $1.57 (current price), down 80.0% from its 52-week high of $7.84 and down 73.8% over the past 90 days. The underlying business context reflects significant stress: the company generated only $3.8M in quarterly revenue, posted a net loss of $23.3M, contracted 33.2% year-over-year in annual revenue, and carries a market cap of $42.0M while remaining unprofitable. A senior executive accumulating a material stake during a steep drawdown and deteriorating operational backdrop warrants investor scrutiny of the transaction rationale.